L 0026

Drug Profile

L 0026

Alternative Names: F 10171

Latest Information Update: 12 Dec 2006

Price : $50

At a glance

  • Originator Pierre Fabre
  • Class Antithrombotics
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis; Thrombosis

Most Recent Events

  • 14 Mar 2000 No-Development-Reported for Coronary artery restenosis in France (Unknown route)
  • 14 Mar 2000 No-Development-Reported for Thrombosis in France (Unknown route)
  • 29 Aug 1996 Phase-I clinical trials for Coronary artery restenosis in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top